NantHealth Inc (NYSE:NH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “

A number of other analysts have also weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and set a $17.00 target price on shares of NantHealth in a report on Monday, September 19th. FBR & Co reiterated a “buy” rating on shares of NantHealth in a report on Thursday, August 18th. Jefferies Group assumed coverage on shares of NantHealth in a report on Monday, June 27th. They set a “buy” rating for the company. First Analysis assumed coverage on shares of NantHealth in a research note on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target for the company. Finally, Cowen and Company assumed coverage on shares of NantHealth in a research note on Monday, June 27th. They issued an “outperform” rating and a $19.00 price target for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. NantHealth presently has an average rating of “Buy” and an average target price of $18.00.

Analyst Recommendations for NantHealth (NYSE:NH)

NantHealth (NYSE:NH) opened at 13.67 on Wednesday. NantHealth has a 52 week low of $9.79 and a 52 week high of $16.63. The stock’s market cap is $1.66 billion. The stock has a 50 day moving average price of $13.16 and a 200-day moving average price of $12.69.

NantHealth (NYSE:NH) last posted its earnings results on Tuesday, August 9th. The company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.26. The firm had revenue of $31.50 million for the quarter, compared to analysts’ expectations of $23.55 million. The company’s quarterly revenue was up 166.9% compared to the same quarter last year. On average, equities analysts anticipate that NantHealth will post ($0.59) EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in NH. Blackstone Group L.P. bought a new position in NantHealth during the second quarter worth about $7,463,000. Jefferies Group LLC acquired a new position in shares of NantHealth during the second quarter worth $6,943,000. Wildcat Capital Management LLC acquired a new position in shares of NantHealth during the second quarter worth $3,008,000. Finally, FMR LLC acquired a new position in shares of NantHealth during the second quarter worth $11,250,000.

About NantHealth

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

5 Day Chart for NYSE:NH

Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.